MedPath

Study of ianalumab with eltrombopag in immune thrombocytopenia (ITP) patients who did not respond to steroid treatment

Phase 3
Conditions
Health Condition 1: D694- Other primary thrombocytopenia
Registration Number
CTRI/2023/05/052406
Lead Sponsor
ovartis Healthcare Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1a.Male or female patients aged 18 years and older on the day of signing the informed consent.

2a.A signed informed consent must be obtained prior to participation in the study.

3a.A diagnosis of primary ITP, with insufficient response to, or relapse after a first-line corticosteroid therapy ± IVIG.

4. Platelet count <30 G/L and assessed need for treatment (per physician’s discretion).

Exclusion Criteria

1.ITP patients who received second-line ITP treatments (other than corticosteroid therapy ± IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (max. one week) before screening are eligible.

2.Patients with key lab abnormalities and patients with Evans syndrome or any other cytopenia

3.Patients with history of clinically significant hematological disorders, or with marked altered hematologic parameters

4.Patients with current or history of life-threatening bleeding

5.Patient that are Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B surface Antigen (HBsAg)/ Hepatitis B core antibody (HBcAB)-positive

6.Patients with known active or uncontrolled infection requiring systemic treatment during screening period

7.Patients with hepatic impairment

8.Patients with concurrent coagulation disorders and/or receiving anti-platelet or anticoagulant medication

9.Female patients who are pregnant or nursing

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to Treatment Failure (TTF)Timepoint: Time to Treatment Failure (TTF)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath